nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—ABCC1—Progesterone—uterine cancer	0.116	0.176	CbGbCtD
Vemurafenib—ABCC1—Dactinomycin—uterine cancer	0.092	0.14	CbGbCtD
Vemurafenib—ABCC1—Epirubicin—uterine cancer	0.0666	0.101	CbGbCtD
Vemurafenib—ABCG2—Dactinomycin—uterine cancer	0.0616	0.0934	CbGbCtD
Vemurafenib—ABCC1—Etoposide—uterine cancer	0.0519	0.0788	CbGbCtD
Vemurafenib—ABCG2—Carboplatin—uterine cancer	0.0414	0.0628	CbGbCtD
Vemurafenib—ABCC1—Doxorubicin—uterine cancer	0.0354	0.0537	CbGbCtD
Vemurafenib—ABCG2—Etoposide—uterine cancer	0.0347	0.0527	CbGbCtD
Vemurafenib—CYP1A2—Progesterone—uterine cancer	0.032	0.0486	CbGbCtD
Vemurafenib—CYP2D6—Progesterone—uterine cancer	0.0264	0.04	CbGbCtD
Vemurafenib—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0253	0.0384	CbGbCtD
Vemurafenib—ABCG2—Doxorubicin—uterine cancer	0.0237	0.036	CbGbCtD
Vemurafenib—CYP3A4—Progesterone—uterine cancer	0.0168	0.0255	CbGbCtD
Vemurafenib—CYP1A2—Etoposide—uterine cancer	0.0143	0.0217	CbGbCtD
Vemurafenib—CYP2D6—Doxorubicin—uterine cancer	0.00805	0.0122	CbGbCtD
Vemurafenib—CYP3A4—Etoposide—uterine cancer	0.0075	0.0114	CbGbCtD
Vemurafenib—CYP3A4—Doxorubicin—uterine cancer	0.00512	0.00777	CbGbCtD
Vemurafenib—BRAF—endometrium—uterine cancer	0.0026	0.0506	CbGeAlD
Vemurafenib—RAF1—myometrium—uterine cancer	0.00246	0.0479	CbGeAlD
Vemurafenib—BRAF—uterus—uterine cancer	0.0024	0.0466	CbGeAlD
Vemurafenib—BRAF—female gonad—uterine cancer	0.00196	0.0381	CbGeAlD
Vemurafenib—BRAF—vagina—uterine cancer	0.00195	0.0379	CbGeAlD
Vemurafenib—RAF1—epithelium—uterine cancer	0.00193	0.0376	CbGeAlD
Vemurafenib—RAF1—uterine cervix—uterine cancer	0.00192	0.0373	CbGeAlD
Vemurafenib—RAF1—smooth muscle tissue—uterine cancer	0.00186	0.0362	CbGeAlD
Vemurafenib—RAF1—decidua—uterine cancer	0.00183	0.0355	CbGeAlD
Vemurafenib—RAF1—renal system—uterine cancer	0.00179	0.0348	CbGeAlD
Vemurafenib—RAF1—endometrium—uterine cancer	0.00173	0.0337	CbGeAlD
Vemurafenib—RAF1—mammalian vulva—uterine cancer	0.00168	0.0326	CbGeAlD
Vemurafenib—RAF1—uterus—uterine cancer	0.0016	0.031	CbGeAlD
Vemurafenib—RAF1—female reproductive system—uterine cancer	0.00144	0.0279	CbGeAlD
Vemurafenib—RAF1—female gonad—uterine cancer	0.00131	0.0254	CbGeAlD
Vemurafenib—RAF1—vagina—uterine cancer	0.0013	0.0252	CbGeAlD
Vemurafenib—BRAF—lymph node—uterine cancer	0.00126	0.0245	CbGeAlD
Vemurafenib—ABCC1—myometrium—uterine cancer	0.00123	0.0239	CbGeAlD
Vemurafenib—ORM1—endometrium—uterine cancer	0.0012	0.0233	CbGeAlD
Vemurafenib—ABCG2—myometrium—uterine cancer	0.00102	0.0198	CbGeAlD
Vemurafenib—ORM1—female reproductive system—uterine cancer	0.000992	0.0193	CbGeAlD
Vemurafenib—ABCC1—uterine cervix—uterine cancer	0.000958	0.0186	CbGeAlD
Vemurafenib—ABCC1—decidua—uterine cancer	0.000913	0.0177	CbGeAlD
Vemurafenib—ABCC1—endometrium—uterine cancer	0.000866	0.0168	CbGeAlD
Vemurafenib—RAF1—lymph node—uterine cancer	0.00084	0.0163	CbGeAlD
Vemurafenib—ABCC1—mammalian vulva—uterine cancer	0.000838	0.0163	CbGeAlD
Vemurafenib—ABCC1—uterus—uterine cancer	0.000798	0.0155	CbGeAlD
Vemurafenib—ABCG2—uterine cervix—uterine cancer	0.000793	0.0154	CbGeAlD
Vemurafenib—ABCG2—decidua—uterine cancer	0.000756	0.0147	CbGeAlD
Vemurafenib—Infestation—Progesterone—uterine cancer	0.000748	0.00482	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Progesterone—uterine cancer	0.000733	0.00473	CcSEcCtD
Vemurafenib—Body temperature increased—Carboplatin—uterine cancer	0.000717	0.00463	CcSEcCtD
Vemurafenib—ABCG2—endometrium—uterine cancer	0.000717	0.0139	CbGeAlD
Vemurafenib—CYP1A2—renal system—uterine cancer	0.000714	0.0139	CbGeAlD
Vemurafenib—ABCG2—mammalian vulva—uterine cancer	0.000694	0.0135	CbGeAlD
Vemurafenib—Weight decreased—Medroxyprogesterone Acetate—uterine cancer	0.000687	0.00443	CcSEcCtD
Vemurafenib—Infestation NOS—Medroxyprogesterone Acetate—uterine cancer	0.000677	0.00437	CcSEcCtD
Vemurafenib—Infestation—Medroxyprogesterone Acetate—uterine cancer	0.000677	0.00437	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Medroxyprogesterone Acetate—uterine cancer	0.000664	0.00428	CcSEcCtD
Vemurafenib—Oedema peripheral—Progesterone—uterine cancer	0.000661	0.00426	CcSEcCtD
Vemurafenib—ABCG2—uterus—uterine cancer	0.000661	0.0128	CbGeAlD
Vemurafenib—Connective tissue disorder—Progesterone—uterine cancer	0.000659	0.00425	CcSEcCtD
Vemurafenib—ABCC1—female gonad—uterine cancer	0.000653	0.0127	CbGeAlD
Vemurafenib—ABCC1—vagina—uterine cancer	0.000649	0.0126	CbGeAlD
Vemurafenib—Erythema multiforme—Progesterone—uterine cancer	0.000634	0.00409	CcSEcCtD
Vemurafenib—Polyp—Epirubicin—uterine cancer	0.00063	0.00406	CcSEcCtD
Vemurafenib—Eye disorder—Progesterone—uterine cancer	0.000627	0.00404	CcSEcCtD
Vemurafenib—Cardiac disorder—Progesterone—uterine cancer	0.000623	0.00402	CcSEcCtD
Vemurafenib—Rash maculo-papular—Etoposide—uterine cancer	0.000621	0.00401	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Dactinomycin—uterine cancer	0.000617	0.00398	CcSEcCtD
Vemurafenib—Folliculitis—Epirubicin—uterine cancer	0.00061	0.00393	CcSEcCtD
Vemurafenib—Angiopathy—Progesterone—uterine cancer	0.000609	0.00393	CcSEcCtD
Vemurafenib—Mediastinal disorder—Progesterone—uterine cancer	0.000605	0.0039	CcSEcCtD
Vemurafenib—Oedema peripheral—Medroxyprogesterone Acetate—uterine cancer	0.000599	0.00386	CcSEcCtD
Vemurafenib—Connective tissue disorder—Medroxyprogesterone Acetate—uterine cancer	0.000598	0.00385	CcSEcCtD
Vemurafenib—Alopecia—Progesterone—uterine cancer	0.000593	0.00382	CcSEcCtD
Vemurafenib—Malnutrition—Progesterone—uterine cancer	0.000584	0.00377	CcSEcCtD
Vemurafenib—Erythema—Progesterone—uterine cancer	0.000584	0.00377	CcSEcCtD
Vemurafenib—Polyp—Doxorubicin—uterine cancer	0.000583	0.00376	CcSEcCtD
Vemurafenib—ORM1—lymph node—uterine cancer	0.00058	0.0113	CbGeAlD
Vemurafenib—Erythema multiforme—Medroxyprogesterone Acetate—uterine cancer	0.000575	0.00371	CcSEcCtD
Vemurafenib—Cyst—Epirubicin—uterine cancer	0.000573	0.0037	CcSEcCtD
Vemurafenib—Eye disorder—Medroxyprogesterone Acetate—uterine cancer	0.000568	0.00367	CcSEcCtD
Vemurafenib—Back pain—Progesterone—uterine cancer	0.000565	0.00364	CcSEcCtD
Vemurafenib—Cardiac disorder—Medroxyprogesterone Acetate—uterine cancer	0.000564	0.00364	CcSEcCtD
Vemurafenib—Folliculitis—Doxorubicin—uterine cancer	0.000564	0.00364	CcSEcCtD
Vemurafenib—Angiopathy—Medroxyprogesterone Acetate—uterine cancer	0.000552	0.00356	CcSEcCtD
Vemurafenib—Paralysis—Epirubicin—uterine cancer	0.000552	0.00356	CcSEcCtD
Vemurafenib—Mediastinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000548	0.00353	CcSEcCtD
Vemurafenib—Chills—Medroxyprogesterone Acetate—uterine cancer	0.000546	0.00352	CcSEcCtD
Vemurafenib—ABCG2—female gonad—uterine cancer	0.000541	0.0105	CbGeAlD
Vemurafenib—ABCG2—vagina—uterine cancer	0.000537	0.0104	CbGeAlD
Vemurafenib—Alopecia—Medroxyprogesterone Acetate—uterine cancer	0.000537	0.00347	CcSEcCtD
Vemurafenib—Cyst—Doxorubicin—uterine cancer	0.00053	0.00342	CcSEcCtD
Vemurafenib—Malnutrition—Medroxyprogesterone Acetate—uterine cancer	0.000529	0.00341	CcSEcCtD
Vemurafenib—Erythema—Medroxyprogesterone Acetate—uterine cancer	0.000529	0.00341	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Dactinomycin—uterine cancer	0.000524	0.00338	CcSEcCtD
Vemurafenib—Dysgeusia—Medroxyprogesterone Acetate—uterine cancer	0.000518	0.00334	CcSEcCtD
Vemurafenib—CYP3A4—renal system—uterine cancer	0.000517	0.01	CbGeAlD
Vemurafenib—Back pain—Medroxyprogesterone Acetate—uterine cancer	0.000512	0.0033	CcSEcCtD
Vemurafenib—Paralysis—Doxorubicin—uterine cancer	0.00051	0.00329	CcSEcCtD
Vemurafenib—Cough—Progesterone—uterine cancer	0.00051	0.00329	CcSEcCtD
Vemurafenib—ALB—lymph node—uterine cancer	0.000509	0.00988	CbGeAlD
Vemurafenib—CYP2D6—renal system—uterine cancer	0.000509	0.00988	CbGeAlD
Vemurafenib—Arthralgia—Progesterone—uterine cancer	0.000497	0.00321	CcSEcCtD
Vemurafenib—Myalgia—Progesterone—uterine cancer	0.000497	0.00321	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.000494	0.00319	CcSEcCtD
Vemurafenib—Anaphylactic shock—Progesterone—uterine cancer	0.000477	0.00308	CcSEcCtD
Vemurafenib—Infection—Progesterone—uterine cancer	0.000474	0.00305	CcSEcCtD
Vemurafenib—Rigors—Epirubicin—uterine cancer	0.000469	0.00303	CcSEcCtD
Vemurafenib—Nervous system disorder—Progesterone—uterine cancer	0.000468	0.00302	CcSEcCtD
Vemurafenib—Skin disorder—Progesterone—uterine cancer	0.000463	0.00299	CcSEcCtD
Vemurafenib—Arthralgia—Medroxyprogesterone Acetate—uterine cancer	0.000451	0.00291	CcSEcCtD
Vemurafenib—Myalgia—Medroxyprogesterone Acetate—uterine cancer	0.000451	0.00291	CcSEcCtD
Vemurafenib—Neoplasm malignant—Epirubicin—uterine cancer	0.000449	0.00289	CcSEcCtD
Vemurafenib—Erythema multiforme—Dactinomycin—uterine cancer	0.000448	0.00289	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.000448	0.00289	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Etoposide—uterine cancer	0.000447	0.00288	CcSEcCtD
Vemurafenib—Hypotension—Progesterone—uterine cancer	0.000445	0.00287	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Progesterone—uterine cancer	0.000434	0.0028	CcSEcCtD
Vemurafenib—Rigors—Doxorubicin—uterine cancer	0.000434	0.0028	CcSEcCtD
Vemurafenib—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.000432	0.00279	CcSEcCtD
Vemurafenib—Infection—Medroxyprogesterone Acetate—uterine cancer	0.000429	0.00277	CcSEcCtD
Vemurafenib—Chills—Dactinomycin—uterine cancer	0.000426	0.00274	CcSEcCtD
Vemurafenib—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000424	0.00273	CcSEcCtD
Vemurafenib—ABCC1—lymph node—uterine cancer	0.00042	0.00816	CbGeAlD
Vemurafenib—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.00042	0.00271	CcSEcCtD
Vemurafenib—Alopecia—Dactinomycin—uterine cancer	0.000419	0.0027	CcSEcCtD
Vemurafenib—Neoplasm malignant—Doxorubicin—uterine cancer	0.000415	0.00268	CcSEcCtD
Vemurafenib—Decreased appetite—Progesterone—uterine cancer	0.000414	0.00267	CcSEcCtD
Vemurafenib—CYP3A4—female reproductive system—uterine cancer	0.000414	0.00804	CbGeAlD
Vemurafenib—Erythema—Dactinomycin—uterine cancer	0.000413	0.00266	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Progesterone—uterine cancer	0.000412	0.00265	CcSEcCtD
Vemurafenib—Fatigue—Progesterone—uterine cancer	0.000411	0.00265	CcSEcCtD
Vemurafenib—Constipation—Progesterone—uterine cancer	0.000408	0.00263	CcSEcCtD
Vemurafenib—CYP2D6—female reproductive system—uterine cancer	0.000407	0.00791	CbGeAlD
Vemurafenib—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.000404	0.0026	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.000394	0.00254	CcSEcCtD
Vemurafenib—Musculoskeletal pain—Epirubicin—uterine cancer	0.000388	0.0025	CcSEcCtD
Vemurafenib—Infestation NOS—Etoposide—uterine cancer	0.000382	0.00247	CcSEcCtD
Vemurafenib—Infestation—Etoposide—uterine cancer	0.000382	0.00247	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Etoposide—uterine cancer	0.000379	0.00245	CcSEcCtD
Vemurafenib—Body temperature increased—Progesterone—uterine cancer	0.000377	0.00243	CcSEcCtD
Vemurafenib—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000376	0.00242	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Etoposide—uterine cancer	0.000375	0.00242	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000373	0.00241	CcSEcCtD
Vemurafenib—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000372	0.0024	CcSEcCtD
Vemurafenib—CYP2D6—female gonad—uterine cancer	0.000371	0.0072	CbGeAlD
Vemurafenib—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000369	0.00238	CcSEcCtD
Vemurafenib—Musculoskeletal pain—Doxorubicin—uterine cancer	0.000359	0.00231	CcSEcCtD
Vemurafenib—Myalgia—Dactinomycin—uterine cancer	0.000352	0.00227	CcSEcCtD
Vemurafenib—Hypersensitivity—Progesterone—uterine cancer	0.000351	0.00227	CcSEcCtD
Vemurafenib—Rash maculo-papular—Epirubicin—uterine cancer	0.000348	0.00225	CcSEcCtD
Vemurafenib—ABCG2—lymph node—uterine cancer	0.000348	0.00675	CbGeAlD
Vemurafenib—Neoplasm—Epirubicin—uterine cancer	0.000346	0.00223	CcSEcCtD
Vemurafenib—Asthenia—Progesterone—uterine cancer	0.000342	0.00221	CcSEcCtD
Vemurafenib—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000342	0.0022	CcSEcCtD
Vemurafenib—Pruritus—Progesterone—uterine cancer	0.000337	0.00218	CcSEcCtD
Vemurafenib—Infection—Dactinomycin—uterine cancer	0.000335	0.00216	CcSEcCtD
Vemurafenib—Diarrhoea—Progesterone—uterine cancer	0.000326	0.0021	CcSEcCtD
Vemurafenib—Erythema multiforme—Etoposide—uterine cancer	0.000325	0.00209	CcSEcCtD
Vemurafenib—Rash maculo-papular—Doxorubicin—uterine cancer	0.000322	0.00208	CcSEcCtD
Vemurafenib—Eye disorder—Etoposide—uterine cancer	0.000321	0.00207	CcSEcCtD
Vemurafenib—Neoplasm—Doxorubicin—uterine cancer	0.000321	0.00207	CcSEcCtD
Vemurafenib—Cardiac disorder—Etoposide—uterine cancer	0.000319	0.00205	CcSEcCtD
Vemurafenib—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000318	0.00205	CcSEcCtD
Vemurafenib—Photosensitivity—Epirubicin—uterine cancer	0.000317	0.00204	CcSEcCtD
Vemurafenib—Dizziness—Progesterone—uterine cancer	0.000315	0.00203	CcSEcCtD
Vemurafenib—Angiopathy—Etoposide—uterine cancer	0.000311	0.00201	CcSEcCtD
Vemurafenib—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00031	0.002	CcSEcCtD
Vemurafenib—Mediastinal disorder—Etoposide—uterine cancer	0.000309	0.002	CcSEcCtD
Vemurafenib—Chills—Etoposide—uterine cancer	0.000308	0.00199	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000307	0.00198	CcSEcCtD
Vemurafenib—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000306	0.00197	CcSEcCtD
Vemurafenib—Alopecia—Etoposide—uterine cancer	0.000303	0.00196	CcSEcCtD
Vemurafenib—Vomiting—Progesterone—uterine cancer	0.000303	0.00196	CcSEcCtD
Vemurafenib—Rash—Progesterone—uterine cancer	0.000301	0.00194	CcSEcCtD
Vemurafenib—Dermatitis—Progesterone—uterine cancer	0.0003	0.00194	CcSEcCtD
Vemurafenib—Headache—Progesterone—uterine cancer	0.000299	0.00193	CcSEcCtD
Vemurafenib—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000296	0.00191	CcSEcCtD
Vemurafenib—Photosensitivity—Doxorubicin—uterine cancer	0.000293	0.00189	CcSEcCtD
Vemurafenib—Decreased appetite—Dactinomycin—uterine cancer	0.000293	0.00189	CcSEcCtD
Vemurafenib—Dysgeusia—Etoposide—uterine cancer	0.000293	0.00189	CcSEcCtD
Vemurafenib—Fatigue—Dactinomycin—uterine cancer	0.000291	0.00187	CcSEcCtD
Vemurafenib—Back pain—Etoposide—uterine cancer	0.000289	0.00186	CcSEcCtD
Vemurafenib—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000286	0.00184	CcSEcCtD
Vemurafenib—Nausea—Progesterone—uterine cancer	0.000283	0.00183	CcSEcCtD
Vemurafenib—Pain in extremity—Epirubicin—uterine cancer	0.000278	0.00179	CcSEcCtD
Vemurafenib—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000275	0.00177	CcSEcCtD
Vemurafenib—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000272	0.00176	CcSEcCtD
Vemurafenib—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000272	0.00176	CcSEcCtD
Vemurafenib—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000271	0.00175	CcSEcCtD
Vemurafenib—Body temperature increased—Dactinomycin—uterine cancer	0.000266	0.00172	CcSEcCtD
Vemurafenib—Cough—Etoposide—uterine cancer	0.000261	0.00168	CcSEcCtD
Vemurafenib—Pain in extremity—Doxorubicin—uterine cancer	0.000257	0.00166	CcSEcCtD
Vemurafenib—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000257	0.00166	CcSEcCtD
Vemurafenib—Dry skin—Epirubicin—uterine cancer	0.000255	0.00164	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000253	0.00163	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.00025	0.00162	CcSEcCtD
Vemurafenib—Hypersensitivity—Dactinomycin—uterine cancer	0.000248	0.0016	CcSEcCtD
Vemurafenib—Anaphylactic shock—Etoposide—uterine cancer	0.000244	0.00157	CcSEcCtD
Vemurafenib—Infection—Etoposide—uterine cancer	0.000242	0.00156	CcSEcCtD
Vemurafenib—Asthenia—Dactinomycin—uterine cancer	0.000242	0.00156	CcSEcCtD
Vemurafenib—Eosinophilia—Epirubicin—uterine cancer	0.000238	0.00154	CcSEcCtD
Vemurafenib—Skin disorder—Etoposide—uterine cancer	0.000237	0.00153	CcSEcCtD
Vemurafenib—Dry skin—Doxorubicin—uterine cancer	0.000236	0.00152	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.000232	0.00149	CcSEcCtD
Vemurafenib—Diarrhoea—Dactinomycin—uterine cancer	0.000231	0.00149	CcSEcCtD
Vemurafenib—Hypotension—Etoposide—uterine cancer	0.000228	0.00147	CcSEcCtD
Vemurafenib—Eosinophilia—Doxorubicin—uterine cancer	0.00022	0.00142	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Epirubicin—uterine cancer	0.000219	0.00142	CcSEcCtD
Vemurafenib—Weight decreased—Epirubicin—uterine cancer	0.000217	0.0014	CcSEcCtD
Vemurafenib—Infestation NOS—Epirubicin—uterine cancer	0.000214	0.00138	CcSEcCtD
Vemurafenib—Infestation—Epirubicin—uterine cancer	0.000214	0.00138	CcSEcCtD
Vemurafenib—Vomiting—Dactinomycin—uterine cancer	0.000214	0.00138	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000213	0.00137	CcSEcCtD
Vemurafenib—Rash—Dactinomycin—uterine cancer	0.000212	0.00137	CcSEcCtD
Vemurafenib—Decreased appetite—Etoposide—uterine cancer	0.000212	0.00137	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Etoposide—uterine cancer	0.000211	0.00136	CcSEcCtD
Vemurafenib—Fatigue—Etoposide—uterine cancer	0.00021	0.00136	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Epirubicin—uterine cancer	0.00021	0.00136	CcSEcCtD
Vemurafenib—Constipation—Etoposide—uterine cancer	0.000209	0.00135	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000203	0.00131	CcSEcCtD
Vemurafenib—Weight decreased—Doxorubicin—uterine cancer	0.000201	0.0013	CcSEcCtD
Vemurafenib—Nausea—Dactinomycin—uterine cancer	0.0002	0.00129	CcSEcCtD
Vemurafenib—Infestation—Doxorubicin—uterine cancer	0.000198	0.00128	CcSEcCtD
Vemurafenib—Infestation NOS—Doxorubicin—uterine cancer	0.000198	0.00128	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000197	0.00127	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000194	0.00125	CcSEcCtD
Vemurafenib—Body temperature increased—Etoposide—uterine cancer	0.000193	0.00124	CcSEcCtD
Vemurafenib—Oedema peripheral—Epirubicin—uterine cancer	0.00019	0.00122	CcSEcCtD
Vemurafenib—Connective tissue disorder—Epirubicin—uterine cancer	0.000189	0.00122	CcSEcCtD
Vemurafenib—Erythema multiforme—Epirubicin—uterine cancer	0.000182	0.00117	CcSEcCtD
Vemurafenib—Eye disorder—Epirubicin—uterine cancer	0.00018	0.00116	CcSEcCtD
Vemurafenib—Hypersensitivity—Etoposide—uterine cancer	0.00018	0.00116	CcSEcCtD
Vemurafenib—Cardiac disorder—Epirubicin—uterine cancer	0.000179	0.00115	CcSEcCtD
Vemurafenib—Oedema peripheral—Doxorubicin—uterine cancer	0.000175	0.00113	CcSEcCtD
Vemurafenib—Asthenia—Etoposide—uterine cancer	0.000175	0.00113	CcSEcCtD
Vemurafenib—Connective tissue disorder—Doxorubicin—uterine cancer	0.000175	0.00113	CcSEcCtD
Vemurafenib—Angiopathy—Epirubicin—uterine cancer	0.000175	0.00113	CcSEcCtD
Vemurafenib—Mediastinal disorder—Epirubicin—uterine cancer	0.000173	0.00112	CcSEcCtD
Vemurafenib—Chills—Epirubicin—uterine cancer	0.000173	0.00111	CcSEcCtD
Vemurafenib—Pruritus—Etoposide—uterine cancer	0.000173	0.00111	CcSEcCtD
Vemurafenib—Alopecia—Epirubicin—uterine cancer	0.00017	0.0011	CcSEcCtD
Vemurafenib—Erythema multiforme—Doxorubicin—uterine cancer	0.000168	0.00109	CcSEcCtD
Vemurafenib—Malnutrition—Epirubicin—uterine cancer	0.000168	0.00108	CcSEcCtD
Vemurafenib—Erythema—Epirubicin—uterine cancer	0.000168	0.00108	CcSEcCtD
Vemurafenib—Diarrhoea—Etoposide—uterine cancer	0.000167	0.00108	CcSEcCtD
Vemurafenib—Eye disorder—Doxorubicin—uterine cancer	0.000166	0.00107	CcSEcCtD
Vemurafenib—Cardiac disorder—Doxorubicin—uterine cancer	0.000165	0.00107	CcSEcCtD
Vemurafenib—Dysgeusia—Epirubicin—uterine cancer	0.000164	0.00106	CcSEcCtD
Vemurafenib—Back pain—Epirubicin—uterine cancer	0.000162	0.00105	CcSEcCtD
Vemurafenib—Angiopathy—Doxorubicin—uterine cancer	0.000162	0.00104	CcSEcCtD
Vemurafenib—Dizziness—Etoposide—uterine cancer	0.000161	0.00104	CcSEcCtD
Vemurafenib—Mediastinal disorder—Doxorubicin—uterine cancer	0.00016	0.00103	CcSEcCtD
Vemurafenib—Chills—Doxorubicin—uterine cancer	0.00016	0.00103	CcSEcCtD
Vemurafenib—Alopecia—Doxorubicin—uterine cancer	0.000157	0.00101	CcSEcCtD
Vemurafenib—Vomiting—Etoposide—uterine cancer	0.000155	0.001	CcSEcCtD
Vemurafenib—Malnutrition—Doxorubicin—uterine cancer	0.000155	0.001	CcSEcCtD
Vemurafenib—Erythema—Doxorubicin—uterine cancer	0.000155	0.001	CcSEcCtD
Vemurafenib—Rash—Etoposide—uterine cancer	0.000154	0.000992	CcSEcCtD
Vemurafenib—Dermatitis—Etoposide—uterine cancer	0.000154	0.000991	CcSEcCtD
Vemurafenib—Headache—Etoposide—uterine cancer	0.000153	0.000985	CcSEcCtD
Vemurafenib—Dysgeusia—Doxorubicin—uterine cancer	0.000152	0.000979	CcSEcCtD
Vemurafenib—Back pain—Doxorubicin—uterine cancer	0.00015	0.000967	CcSEcCtD
Vemurafenib—Cough—Epirubicin—uterine cancer	0.000146	0.000943	CcSEcCtD
Vemurafenib—Nausea—Etoposide—uterine cancer	0.000145	0.000934	CcSEcCtD
Vemurafenib—Myalgia—Epirubicin—uterine cancer	0.000143	0.00092	CcSEcCtD
Vemurafenib—Arthralgia—Epirubicin—uterine cancer	0.000143	0.00092	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000142	0.000913	CcSEcCtD
Vemurafenib—Anaphylactic shock—Epirubicin—uterine cancer	0.000137	0.000882	CcSEcCtD
Vemurafenib—Infection—Epirubicin—uterine cancer	0.000136	0.000876	CcSEcCtD
Vemurafenib—Cough—Doxorubicin—uterine cancer	0.000135	0.000872	CcSEcCtD
Vemurafenib—Nervous system disorder—Epirubicin—uterine cancer	0.000134	0.000865	CcSEcCtD
Vemurafenib—Skin disorder—Epirubicin—uterine cancer	0.000133	0.000856	CcSEcCtD
Vemurafenib—Arthralgia—Doxorubicin—uterine cancer	0.000132	0.000851	CcSEcCtD
Vemurafenib—Myalgia—Doxorubicin—uterine cancer	0.000132	0.000851	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000131	0.000845	CcSEcCtD
Vemurafenib—Hypotension—Epirubicin—uterine cancer	0.000128	0.000824	CcSEcCtD
Vemurafenib—Anaphylactic shock—Doxorubicin—uterine cancer	0.000126	0.000816	CcSEcCtD
Vemurafenib—Infection—Doxorubicin—uterine cancer	0.000126	0.000811	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000125	0.000803	CcSEcCtD
Vemurafenib—Nervous system disorder—Doxorubicin—uterine cancer	0.000124	0.0008	CcSEcCtD
Vemurafenib—Skin disorder—Doxorubicin—uterine cancer	0.000123	0.000792	CcSEcCtD
Vemurafenib—Decreased appetite—Epirubicin—uterine cancer	0.000119	0.000767	CcSEcCtD
Vemurafenib—Hypotension—Doxorubicin—uterine cancer	0.000118	0.000762	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000118	0.000761	CcSEcCtD
Vemurafenib—Fatigue—Epirubicin—uterine cancer	0.000118	0.00076	CcSEcCtD
Vemurafenib—Constipation—Epirubicin—uterine cancer	0.000117	0.000754	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000115	0.000743	CcSEcCtD
Vemurafenib—Decreased appetite—Doxorubicin—uterine cancer	0.00011	0.000709	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000109	0.000704	CcSEcCtD
Vemurafenib—Fatigue—Doxorubicin—uterine cancer	0.000109	0.000703	CcSEcCtD
Vemurafenib—Constipation—Doxorubicin—uterine cancer	0.000108	0.000698	CcSEcCtD
Vemurafenib—Body temperature increased—Epirubicin—uterine cancer	0.000108	0.000697	CcSEcCtD
Vemurafenib—Hypersensitivity—Epirubicin—uterine cancer	0.000101	0.00065	CcSEcCtD
Vemurafenib—Body temperature increased—Doxorubicin—uterine cancer	0.0001	0.000645	CcSEcCtD
Vemurafenib—Asthenia—Epirubicin—uterine cancer	9.81e-05	0.000633	CcSEcCtD
Vemurafenib—Pruritus—Epirubicin—uterine cancer	9.67e-05	0.000624	CcSEcCtD
Vemurafenib—Diarrhoea—Epirubicin—uterine cancer	9.35e-05	0.000603	CcSEcCtD
Vemurafenib—Hypersensitivity—Doxorubicin—uterine cancer	9.32e-05	0.000601	CcSEcCtD
Vemurafenib—Asthenia—Doxorubicin—uterine cancer	9.08e-05	0.000585	CcSEcCtD
Vemurafenib—Dizziness—Epirubicin—uterine cancer	9.04e-05	0.000583	CcSEcCtD
Vemurafenib—Pruritus—Doxorubicin—uterine cancer	8.95e-05	0.000577	CcSEcCtD
Vemurafenib—Vomiting—Epirubicin—uterine cancer	8.69e-05	0.000561	CcSEcCtD
Vemurafenib—Diarrhoea—Doxorubicin—uterine cancer	8.65e-05	0.000558	CcSEcCtD
Vemurafenib—Rash—Epirubicin—uterine cancer	8.62e-05	0.000556	CcSEcCtD
Vemurafenib—Dermatitis—Epirubicin—uterine cancer	8.61e-05	0.000555	CcSEcCtD
Vemurafenib—Headache—Epirubicin—uterine cancer	8.56e-05	0.000552	CcSEcCtD
Vemurafenib—Dizziness—Doxorubicin—uterine cancer	8.36e-05	0.00054	CcSEcCtD
Vemurafenib—Nausea—Epirubicin—uterine cancer	8.12e-05	0.000524	CcSEcCtD
Vemurafenib—Vomiting—Doxorubicin—uterine cancer	8.04e-05	0.000519	CcSEcCtD
Vemurafenib—Rash—Doxorubicin—uterine cancer	7.98e-05	0.000514	CcSEcCtD
Vemurafenib—Dermatitis—Doxorubicin—uterine cancer	7.97e-05	0.000514	CcSEcCtD
Vemurafenib—Headache—Doxorubicin—uterine cancer	7.92e-05	0.000511	CcSEcCtD
Vemurafenib—Nausea—Doxorubicin—uterine cancer	7.51e-05	0.000485	CcSEcCtD
Vemurafenib—ALB—Metabolism—AKR1B1—uterine cancer	2.79e-05	0.000207	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—AKT1—uterine cancer	2.78e-05	0.000206	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—SOCS3—uterine cancer	2.76e-05	0.000205	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—STK11—uterine cancer	2.76e-05	0.000205	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.76e-05	0.000205	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CYP11A1—uterine cancer	2.7e-05	0.000201	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SRD5A2—uterine cancer	2.7e-05	0.0002	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NDUFB11—uterine cancer	2.7e-05	0.0002	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—PIK3CA—uterine cancer	2.66e-05	0.000198	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—AKT1—uterine cancer	2.63e-05	0.000195	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.62e-05	0.000195	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—PIK3CA—uterine cancer	2.62e-05	0.000194	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SOCS3—uterine cancer	2.58e-05	0.000192	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—KRAS—uterine cancer	2.58e-05	0.000191	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AKR1C3—uterine cancer	2.55e-05	0.00019	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—ERBB2—uterine cancer	2.48e-05	0.000184	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.48e-05	0.000184	CbGpPWpGaD
Vemurafenib—RAF1—Neuronal System—HRAS—uterine cancer	2.47e-05	0.000183	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CDKN2B—uterine cancer	2.47e-05	0.000183	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—HRAS—uterine cancer	2.46e-05	0.000183	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—CTNNB1—uterine cancer	2.46e-05	0.000183	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKR1C3—uterine cancer	2.45e-05	0.000182	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CDKN2B—uterine cancer	2.44e-05	0.000181	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—HRAS—uterine cancer	2.42e-05	0.00018	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CDKN2B—uterine cancer	2.42e-05	0.00018	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IGF1R—uterine cancer	2.4e-05	0.000178	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PGR—uterine cancer	2.39e-05	0.000177	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—ERBB2—uterine cancer	2.38e-05	0.000177	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—FGFR2—uterine cancer	2.3e-05	0.000171	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—STAR—uterine cancer	2.3e-05	0.000171	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AKR1B1—uterine cancer	2.3e-05	0.000171	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CDKN1B—uterine cancer	2.3e-05	0.000171	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—EP300—uterine cancer	2.29e-05	0.00017	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—YWHAE—uterine cancer	2.28e-05	0.000169	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—STK11—uterine cancer	2.26e-05	0.000168	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CYP19A1—uterine cancer	2.26e-05	0.000168	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SMAD3—uterine cancer	2.26e-05	0.000167	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—EP300—uterine cancer	2.24e-05	0.000166	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SMAD3—uterine cancer	2.23e-05	0.000165	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	2.22e-05	0.000165	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SMAD3—uterine cancer	2.21e-05	0.000164	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CDKN1B—uterine cancer	2.21e-05	0.000164	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—HRAS—uterine cancer	2.19e-05	0.000163	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—POLD1—uterine cancer	2.19e-05	0.000162	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FBXW7—uterine cancer	2.18e-05	0.000162	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CTNNB1—uterine cancer	2.17e-05	0.000161	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—VEGFA—uterine cancer	2.17e-05	0.000161	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—FGFR2—uterine cancer	2.15e-05	0.00016	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—AKT1—uterine cancer	2.14e-05	0.000159	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—NRAS—uterine cancer	2.14e-05	0.000159	CbGpPWpGaD
Vemurafenib—RAF1—Disease—FGFR2—uterine cancer	2.13e-05	0.000158	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—VEGFA—uterine cancer	2.12e-05	0.000158	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.12e-05	0.000158	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—PTEN—uterine cancer	2.12e-05	0.000157	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—FGFR2—uterine cancer	2.11e-05	0.000156	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—NRAS—uterine cancer	2.1e-05	0.000156	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NDUFB11—uterine cancer	2.08e-05	0.000155	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SRD5A2—uterine cancer	2.08e-05	0.000155	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AKR1C1—uterine cancer	2.05e-05	0.000152	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MTHFR—uterine cancer	2.05e-05	0.000152	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—PTEN—uterine cancer	2.03e-05	0.000151	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MTHFR—uterine cancer	2.03e-05	0.000151	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.02e-05	0.00015	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—EP300—uterine cancer	2.02e-05	0.00015	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—STK11—uterine cancer	1.99e-05	0.000148	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CYP19A1—uterine cancer	1.99e-05	0.000148	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKR1B1—uterine cancer	1.95e-05	0.000145	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—STAR—uterine cancer	1.95e-05	0.000145	CbGpPWpGaD
Vemurafenib—BRAF—Disease—ERBB2—uterine cancer	1.93e-05	0.000143	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.93e-05	0.000143	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—STK11—uterine cancer	1.91e-05	0.000142	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCL2—uterine cancer	1.9e-05	0.000141	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—NRAS—uterine cancer	1.89e-05	0.00014	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ESR1—uterine cancer	1.84e-05	0.000137	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—KRAS—uterine cancer	1.84e-05	0.000137	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—RRM2—uterine cancer	1.82e-05	0.000135	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—NRAS—uterine cancer	1.81e-05	0.000135	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—POLD1—uterine cancer	1.81e-05	0.000134	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—KRAS—uterine cancer	1.81e-05	0.000134	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CDKN1B—uterine cancer	1.79e-05	0.000133	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SOCS3—uterine cancer	1.79e-05	0.000133	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—DCN—uterine cancer	1.77e-05	0.000131	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	1.73e-05	0.000129	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CDH1—uterine cancer	1.71e-05	0.000127	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CDKN2B—uterine cancer	1.71e-05	0.000127	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—MTHFR—uterine cancer	1.7e-05	0.000126	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AKR1C1—uterine cancer	1.69e-05	0.000125	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CTNNB1—uterine cancer	1.69e-05	0.000125	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP11A1—uterine cancer	1.67e-05	0.000124	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IGF1R—uterine cancer	1.66e-05	0.000123	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—PIK3CA—uterine cancer	1.66e-05	0.000123	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PTEN—uterine cancer	1.65e-05	0.000122	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—KRAS—uterine cancer	1.63e-05	0.000121	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCL2—uterine cancer	1.62e-05	0.00012	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—uterine cancer	1.61e-05	0.000119	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AKR1C3—uterine cancer	1.58e-05	0.000117	CbGpPWpGaD
Vemurafenib—BRAF—Disease—EP300—uterine cancer	1.57e-05	0.000116	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—HRAS—uterine cancer	1.56e-05	0.000116	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—KRAS—uterine cancer	1.56e-05	0.000116	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SMAD3—uterine cancer	1.56e-05	0.000116	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—HRAS—uterine cancer	1.54e-05	0.000114	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—POLD1—uterine cancer	1.53e-05	0.000114	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—RRM2—uterine cancer	1.51e-05	0.000112	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—STAR—uterine cancer	1.51e-05	0.000112	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKR1B1—uterine cancer	1.51e-05	0.000112	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CXCL8—uterine cancer	1.5e-05	0.000111	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.5e-05	0.000111	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—MTHFR—uterine cancer	1.5e-05	0.000111	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—PIK3CA—uterine cancer	1.49e-05	0.000111	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FGFR2—uterine cancer	1.49e-05	0.000111	CbGpPWpGaD
Vemurafenib—BRAF—Disease—NRAS—uterine cancer	1.47e-05	0.000109	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—DCN—uterine cancer	1.46e-05	0.000109	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ERBB2—uterine cancer	1.45e-05	0.000107	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—PIK3CA—uterine cancer	1.43e-05	0.000106	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKR1C1—uterine cancer	1.43e-05	0.000106	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—AKT1—uterine cancer	1.42e-05	0.000105	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—HRAS—uterine cancer	1.38e-05	0.000103	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—AKT1—uterine cancer	1.38e-05	0.000103	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP11A1—uterine cancer	1.38e-05	0.000102	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—AKT1—uterine cancer	1.36e-05	0.000101	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ERBB2—uterine cancer	1.35e-05	0.0001	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CDKN1B—uterine cancer	1.34e-05	9.94e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—ERBB2—uterine cancer	1.34e-05	9.91e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HRAS—uterine cancer	1.33e-05	9.85e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—ERBB2—uterine cancer	1.32e-05	9.82e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AKR1C3—uterine cancer	1.3e-05	9.66e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCL8—uterine cancer	1.28e-05	9.51e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—RRM2—uterine cancer	1.28e-05	9.47e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ESR1—uterine cancer	1.27e-05	9.45e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CTNNB1—uterine cancer	1.27e-05	9.39e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—KRAS—uterine cancer	1.26e-05	9.38e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CDKN1B—uterine cancer	1.25e-05	9.29e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—DCN—uterine cancer	1.24e-05	9.19e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CDKN1B—uterine cancer	1.24e-05	9.18e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PTEN—uterine cancer	1.23e-05	9.15e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—STK11—uterine cancer	1.23e-05	9.11e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP19A1—uterine cancer	1.23e-05	9.11e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CDKN1B—uterine cancer	1.23e-05	9.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—AKT1—uterine cancer	1.22e-05	9.06e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—EP300—uterine cancer	1.21e-05	8.96e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—NRAS—uterine cancer	1.2e-05	8.94e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CTNNB1—uterine cancer	1.18e-05	8.78e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—POLD1—uterine cancer	1.18e-05	8.77e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EP300—uterine cancer	1.18e-05	8.73e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—AKT1—uterine cancer	1.17e-05	8.7e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CTNNB1—uterine cancer	1.17e-05	8.67e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP11A1—uterine cancer	1.17e-05	8.66e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PIK3CA—uterine cancer	1.16e-05	8.62e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CTNNB1—uterine cancer	1.16e-05	8.59e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PTEN—uterine cancer	1.15e-05	8.55e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.15e-05	8.55e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—uterine cancer	1.14e-05	8.49e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTEN—uterine cancer	1.14e-05	8.45e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NRAS—uterine cancer	1.13e-05	8.38e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTEN—uterine cancer	1.13e-05	8.38e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL2—uterine cancer	1.12e-05	8.32e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKR1C1—uterine cancer	1.11e-05	8.2e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKR1C3—uterine cancer	1.1e-05	8.18e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—NRAS—uterine cancer	1.1e-05	8.17e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EP300—uterine cancer	1.1e-05	8.16e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.1e-05	8.16e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EP300—uterine cancer	1.09e-05	8.06e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EP300—uterine cancer	1.08e-05	7.99e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HRAS—uterine cancer	1.07e-05	7.97e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—uterine cancer	1.04e-05	7.73e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—KRAS—uterine cancer	1.04e-05	7.69e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NRAS—uterine cancer	1.03e-05	7.63e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NRAS—uterine cancer	1.02e-05	7.54e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—STK11—uterine cancer	1.01e-05	7.52e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP19A1—uterine cancer	1.01e-05	7.52e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NRAS—uterine cancer	1.01e-05	7.47e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—RRM2—uterine cancer	9.85e-06	7.31e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—KRAS—uterine cancer	9.72e-06	7.21e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—DCN—uterine cancer	9.56e-06	7.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PIK3CA—uterine cancer	9.52e-06	7.07e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—AKT1—uterine cancer	9.48e-06	7.04e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KRAS—uterine cancer	9.47e-06	7.03e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTEN—uterine cancer	9.45e-06	7.02e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ERBB2—uterine cancer	9.35e-06	6.94e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MTHFR—uterine cancer	9.23e-06	6.85e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—EP300—uterine cancer	9.01e-06	6.69e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP11A1—uterine cancer	9.01e-06	6.69e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PIK3CA—uterine cancer	8.93e-06	6.63e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL8—uterine cancer	8.87e-06	6.58e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KRAS—uterine cancer	8.85e-06	6.57e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—HRAS—uterine cancer	8.81e-06	6.54e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KRAS—uterine cancer	8.74e-06	6.49e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PIK3CA—uterine cancer	8.7e-06	6.46e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KRAS—uterine cancer	8.67e-06	6.43e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CDKN1B—uterine cancer	8.66e-06	6.43e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—uterine cancer	8.64e-06	6.41e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—STK11—uterine cancer	8.59e-06	6.37e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP19A1—uterine cancer	8.59e-06	6.37e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKR1C3—uterine cancer	8.51e-06	6.31e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTEN—uterine cancer	8.32e-06	6.17e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—HRAS—uterine cancer	8.26e-06	6.13e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CTNNB1—uterine cancer	8.18e-06	6.07e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PIK3CA—uterine cancer	8.13e-06	6.03e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	8.13e-06	6.03e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	8.06e-06	5.98e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HRAS—uterine cancer	8.05e-06	5.97e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PIK3CA—uterine cancer	8.03e-06	5.96e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTEN—uterine cancer	7.97e-06	5.92e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PIK3CA—uterine cancer	7.96e-06	5.91e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—EP300—uterine cancer	7.93e-06	5.89e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—uterine cancer	7.87e-06	5.84e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AKT1—uterine cancer	7.78e-06	5.77e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.69e-06	5.71e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MTHFR—uterine cancer	7.62e-06	5.65e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EP300—uterine cancer	7.6e-06	5.64e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HRAS—uterine cancer	7.52e-06	5.58e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HRAS—uterine cancer	7.43e-06	5.52e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HRAS—uterine cancer	7.37e-06	5.47e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—AKT1—uterine cancer	7.3e-06	5.41e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—uterine cancer	7.2e-06	5.34e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NRAS—uterine cancer	7.11e-06	5.28e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—AKT1—uterine cancer	7.11e-06	5.27e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CA—uterine cancer	6.67e-06	4.95e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AKT1—uterine cancer	6.64e-06	4.93e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—STK11—uterine cancer	6.63e-06	4.92e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP19A1—uterine cancer	6.63e-06	4.92e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—AKT1—uterine cancer	6.56e-06	4.87e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—AKT1—uterine cancer	6.5e-06	4.83e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MTHFR—uterine cancer	6.45e-06	4.79e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KRAS—uterine cancer	6.12e-06	4.54e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CA—uterine cancer	5.87e-06	4.35e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.69e-06	4.22e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CA—uterine cancer	5.63e-06	4.17e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AKT1—uterine cancer	5.45e-06	4.04e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—uterine cancer	5.44e-06	4.04e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HRAS—uterine cancer	5.2e-06	3.86e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTEN—uterine cancer	5.13e-06	3.81e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MTHFR—uterine cancer	4.98e-06	3.7e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—EP300—uterine cancer	4.89e-06	3.63e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AKT1—uterine cancer	4.79e-06	3.56e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT1—uterine cancer	4.6e-06	3.41e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTEN—uterine cancer	4.24e-06	3.14e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—EP300—uterine cancer	4.04e-06	3e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CA—uterine cancer	3.62e-06	2.69e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTEN—uterine cancer	3.59e-06	2.66e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—EP300—uterine cancer	3.42e-06	2.54e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CA—uterine cancer	2.99e-06	2.22e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AKT1—uterine cancer	2.96e-06	2.2e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTEN—uterine cancer	2.77e-06	2.06e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—EP300—uterine cancer	2.64e-06	1.96e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CA—uterine cancer	2.53e-06	1.88e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AKT1—uterine cancer	2.44e-06	1.81e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKT1—uterine cancer	2.07e-06	1.54e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.95e-06	1.45e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKT1—uterine cancer	1.6e-06	1.18e-05	CbGpPWpGaD
